HONG KONG, 7 MAY 2025 — On 30 April 2025, Hong Kong-Shenzhen Innovation and Technology Park Limited (HSITPL) and Pfizer Corporation Hong Kong Limited (Pfizer) signed a Memorandum of Understanding (MoU) at the Hong Kong-Shenzhen Innovation and Technology Park, the Hong Kong Park in the Loop (HSITP). With an aim to leapfrog the health and medical innovation in Hong Kong and the Greater Bay Area (GBA), this strategic partnership will leverage the unique strengths of both organizations to propel the advancement of biotechnology sector in the region, with the Hong Kong Park positioned as the preeminent hub fostering biotech talent development and clinical trials.

The MoU outlines a collaborative framework focusing on three pivotal initiatives:

1. Expanding Biotech Talent: HSITPL and Pfizer will jointly endeavour to broaden Hong Kong’s biotechnology talent pool by attracting global capability centres to establish and expand operations within the region. This long-term initiative is projected to commence in 2027.
2. Accelerating Clinical Trials and Real-world Evidence (RWE) Generation: The collaboration aims to enhance the efficacy of clinical trial operations and generate RWE across Hong Kong and GBA cities, with implementation plans set for 2026.
3. Support for Incubation and Acceleration Programs: The collaboration will seek to make use of the experience and proven track records of Pfizer in incubation and acceleration to support HSITP to nurture a dynamic environment for biotech innovation and growth in the Park.

Mr. Vincent Ma, Chief Executive Officer of HSITPL said, “We are delighted to collaborate with Pfizer, a global pharmaceutical leader, to pursue a visionary course in our journey towards the development of a world-class innovation and technology (I&T) hub. This partnership will further enable us to accelerate frontier technology breakthroughs in the Hong Kong Park, attracting top-tier talents and resources to foster a dynamic and resilient ecosystem, making full use of Hong Kong’s strengths as a ‘super connector’ and ‘super value-adder’.”

Mr. Krishnamoorthy Sundaresan, General Manager, Pfizer Hong Kong and Macau, highlighted, “Pfizer is continuously working to advance the discovery and development of science that can bring greater outcomes and hope to patients everywhere. This collaboration is well-aligned with our broader ‘Pfizer China 2030 Strategy’ focused on accelerating the development of innovative medicines and access and supporting local biotech development. We are proud to work with HSITPL to strengthen market-level medical capabilities, drive progress in clinical development and elevate healthcare outcomes for communities in the region.”

The collaboration also presents an opportunity for Pfizer and HSITPL to identify potential joint biomedical research and commercialization projects.

– Ends –

About HSITP
Located in the Northern Metropolis of Hong Kong, HSITP spans approximately 87.7 hectares of land, adjacent to the Lok Ma Chau Spur Line and the Lok Ma Chau control points. The Hong Kong Park, together with the Shenzhen Park on the other side of the river, form the Hetao Shenzhen Hong Kong Science and Technology Innovation Co-operation Zone (the Co-operation Zone). Under the country’s staunch support, the Co-operation Zone is a brand-new testbed for pilot cross-boundary policies, in line with the principle of “one zone, two parks” at “one river, two banks” under the auspices of “One Country, Two Systems”.

HSITP strives to evolve into a world-class I&T hub by advancing its development in four major directions: to build a world-class industry-academia-research platform, to establish an internationally competitive research and development transformation and pilot production base for industries; to foster a hub for pooling global innovation and technology resources, and to cultivate a testing ground for institutional and policy innovation.

Cultivating a testing ground for institutional and policy innovation, HSITP will develop in accordance with the basic principles of “being free and open, connecting the Mainland and the rest of the world, and facilitating movement”. The Hong Kong and Shenzhen governments also plan to implement innovative policy measures to promote the convenient cross-boundary flow of innovation elements.

The development of HSITP will be completed in batches, aiming to put basically in place a highly efficient mechanism for synergistic development of innovation with the Shenzhen Park by 2030, laying a solid foundation for further promoting the comprehensive development of the Hong Kong Park. By 2035, a comprehensive development pattern will emerge, facilitating the advancement of the Co-operation Zone into a global leader in I&T.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.pfizer.com.hk and like us on YouTube at www.youtube.com/c/pfizerhongkong.

(Joint release with HSITPL)